Events

« All Events

World ADC 2025

November 3 - November 6

Join us at Booth #13

Town & Country Resort, San Diego, CA

If you are attending World ADC in San Diego this November, we would love to connect with you!

Avid Bioservices has extensive experience supporting Antibody-Drug Conjugate (ADC) programs, helping innovators navigate the complexities of biologics development and manufacturing. Whether you’re advancing a novel ADC candidate or preparing for commercial scale-up, our team is ready to discuss how we can support your goals with tailored CDMO solutions.

 

 

Why Meet with Avid Bioservices?

• 30+ years of biologics development experience, including ADCs
• Flexible CDMO services from clinical to commercial production
• Unparalleled quality and operational excellence
• Best-in-class U.S.-based facilities
• We approach every customer and molecule with personalized care
• Onshoring with a U.S.-based CDMO reduces supply chain risks and helps navigate global tariffs

 

Meet Our Experts

Our team will be onsite to discuss:

• ADC process development and scale-up strategies
• Payload conjugation and purification approaches
• Analytical characterization and QC for complex molecules
• CGMP manufacturing for high potency biologics
• How onshoring can enhance supply chain resilience and reduce geopolitical risk

 

Don’t miss this opportunity to connect with Avid Bioservices at Booth #13 and bring your vision to life!

 

Add to calendar

• Google Calendar
• iCalendar
• Outlook 365
• Outlook Live

Details

Start:

November 3

End:

November 6

Event Category:

Conference

Venue

Town and Country San Diego

500 Hotel Circle
San Diego, CA 92108 United States

Related Events

• 

  Biomanufacturing World Summit

  November 10 - November 12

News

• Avid Bioservices Welcomes Kenneth Bilenberg as New CEO

  September 15, 2025

  Tustin, CA, USA – September 15, 2025 – Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kenneth Bilenberg as its new […]

  Read more

• CHO Plus Enters into Project Agreement with BARDA’s BioMaP Consortium to Develop High Productivity Cell Lines for Filovirus Monoclonal Antibody Production

  August 5, 2025

  SOUTH SAN FRANCISCO, California – August 05, 2025 – Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical […]

  Read more

• GHO & Ampersand Complete Acquisition of Avid Bioservices

  February 5, 2025

  Download PDF Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completed GHO […]

  Read more

• Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger

  February 5, 2025

  Download PDFAvid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger TUSTIN, Calif., February 5, 2025 — Avid […]

  Read more

• Avid Stockholders Approve Transaction with GHO and Ampersand

  January 30, 2025

  Download PDFTUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve […]

  Read more

• Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction

  November 6, 2024

  Download PDFTUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing […]

  Read more

< View Older News